ASTRAZENECA PLCAZN決算レポート
Nasdaq · pharmaceutical industry
AstraZeneca plc (AZ) is a Swedish-British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
AZN Q2 2025 Key Financial Metrics
売上高
$14.5B
粗利益
$12.0B
営業利益
$3.5B
純利益
$2.4B
粗利益率
82.9%
営業利益率
24.3%
純利益率
16.9%
前年比成長
11.7%
EPS
$1.57
資金フロー
ASTRAZENECA PLC Q2 2025 財務サマリー
ASTRAZENECA PLC reported revenue of $14.5B (up 11.7% YoY) for Q2 2025, with a net profit of $2.4B (up 27.0% YoY) (16.9% margin). Cost of goods sold was $2.5B, operating expenses totaled $8.5B.
主要財務指標
| 総売上高 | $14.5B |
|---|---|
| 純利益 | $2.4B |
| 粗利益率 | 82.9% |
| 営業利益率 | 24.3% |
| 報告期間 | Q2 2025 |
ASTRAZENECA PLC 四半期売上・純利益の履歴
ASTRAZENECA PLC quarterly results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| 四半期 | 売上高 | 売上前年比 | 純利益 | 純利益率 |
|---|---|---|---|---|
| Q2 2025 | $14.5B | +11.7% | $2.4B | 16.9% |
| Q2 2024 | $12.9B | +13.3% | $1.9B | 14.9% |
| Q2 2023 | $11.4B | +6.0% | $1.8B | 15.9% |
| Q2 2022 | $10.8B | +31.0% | $360.0M | 3.3% |
損益計算書
| Q2 2022 | Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|---|
| 売上高 | $10.77B | $11.42B | $12.94B | $14.46B |
| 前年比成長 | 31.0% | 6.0% | 13.3% | 11.7% |
貸借対照表
| Q2 2022 | Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|---|
| 総資産 | $96.58B | $96.54B | $104.34B | $112.42B |
| 総負債 | $60.63B | $59.13B | $64.74B | $67.61B |
| 株主資本 | $35.95B | $37.42B | $39.60B | $44.81B |
キャッシュフロー
この期間のデータはありません